Mary C Beckerle sold $1.0M of EXEL
director at EXELIXIS, INC.. 24,622 shares at an average of $41.93, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.0M at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000939767-25-000134, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | MOption exercise Common Stock | +5,784 | $23.24 | $134k | 46,002 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -5,784 | $42.03 | $243k | 40,218 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -18,838 | $41.90 | $789k | 21,380 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Option (right to buy)derivative | -5,784 | $0.00 | $0 | 16,710 | Nov 13, 2025 |
Related signals
Other insiders at EXELIXIS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | EXELbuy EXELIXIS, INC. | David Edward Johnson director | $1.2M 27,532 shares | +2% | |
| 60Notable | EXELIXIS, INC. | Patrick J. Haley EVP, Commercial | $3.0M 72,230 shares | -18% | |
| 55Moderate | EXELIXIS, INC. | Dana Aftab EVP, Research and Development | $2.1M 48,383 shares | -7% | |
| 55Moderate | EXELIXIS, INC. | Stelios Papadopoulos director | $4.4M 100,000 shares | -8% | |
| 24Weak | EXELIXIS, INC. | Jack L Wyszomierski director | $325k 7,535 shares | -2% | |
| 42Moderate | EXELIXIS, INC. | Sue Gail Eckhardt director | $805k 18,838 shares | -47% | |
| 47Moderate | EXELIXIS, INC. | Tomas J. Heyman director | $201k 4,544 shares | -12% | |
| 55Moderate | EXELIXIS, INC. | Patrick J. Haley EVP, Commercial | $1.5M 34,387 shares | -8% | |
| 45Moderate | EXELIXIS, INC. | Amy C. Peterson EVP Prod Dev & Med Aff & CMO | $3.3M 72,776 shares | -14% | |
| 30Weak | EXELIXIS, INC. | Patrick J. Haley EVP, Commercial | $6.5M 136,383 shares | -27% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.